With the clinical data from RESOVIR-1, where resomelagon was tested in severe COVID-19, and preclinical data from the RESOVIR collaboration, SynAct Pharma has contributed to the first ever published demonstration of the effects of a pro-resolving molecule in the context of severe infection in humans.
Host-directed therapies target the effects of the viral infection, in our case induced inflammatory diseases, independently of which virus type or virus strain, is causing the disease. Thus, applying resomelagon as host-directed therapy offers a treatment opportunity in a wide range of virus infections causing inflammatory diseases.
Focusing on dengue fever as an example of arboviral infections gives an opportunity to run a proof-of-concept study, RESOVIR-2, as part of the RESOVIR collaboration.
Other arboviral infections of interest could be Chikungunya, where preclinical data already supports an effect, and Zika virus.
Respiratory infections such as influenza and respiratory syncytial (RS) virus other examples of virus infections where a subset of patients are at risk for hospitalization (due to acute respiratory distress syndrome (ARDS)), similarly to what is seen with COVID-19 infections.